Predicting effectiveness of PARP inhibitors in ovarian cancer maintenance treatment
PAOLA-1 Ancillary Study: Retrospective Validation of KELIM as a Predictive and Prognostic Factor for Maintenance Treatment With PARP Inhibitor After Platinum-Based Chemotherapy in First-Line Ovarian Cancer
This study is trying to see if a specific score can help predict which women with ovarian cancer will benefit from a maintenance treatment using PARP inhibitors after their first round of chemotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 327 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Arcagy/ Gineco Group Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 24 sites (Angers and 23 other locations) |
| Trial ID | NCT06660147 on ClinicalTrials.gov |
What this trial studies
This study aims to validate KELIM as a predictive and prognostic factor for the effectiveness of maintenance treatment with PARP inhibitors in patients with ovarian cancer who have undergone first-line chemotherapy. By analyzing data from patients randomized in the PAOLA-1 study, the research seeks to identify which patients are most likely to benefit from this treatment. The observational nature of the study allows for real-world insights into treatment outcomes based on KELIM scores.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with ovarian cancer who have been randomized in the PAOLA-1 study and have completed first-line chemotherapy.
Not a fit: Patients who oppose the use of their data for research purposes will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help tailor maintenance treatments to patients who are most likely to benefit, improving outcomes in ovarian cancer care.
How similar studies have performed: Other studies have shown promise in using predictive factors for treatment outcomes in ovarian cancer, suggesting that this approach may be beneficial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients randomised in the PAOLA-1 study - Exclusion Criteria:Opposition to the use of your data for research purposes. \-
Where this trial is running
Angers and 23 other locations
- ICO Paul Papin — Angers, France (Recruiting)
- Sainte-Catherine Institut du Cancer Avignon-Provence — Avignon, France (Recruiting)
- CHRU Besançon - Hôpital Jean Minjoz — Besançon, France (Recruiting)
- Polyclinique Bordeaux Nord — Bordeaux, France (Recruiting)
- Centre François Baclesse — Caen, France (Recruiting)
- Centre Jean Perrin — Clermont-Ferrand, France (Recruiting)
- CHU Grenoble-Alpes - Site Nord (La Tronche) — Grenoble, France (Recruiting)
- Centre Hospitalier Départemental de Vendée — La Roche-sur-Yon, France (Recruiting)
- Centre Azuréen de Cancérologie — Mougins, France (Recruiting)
- Hôpital Privé du Confluent — Nantes, France (Recruiting)
- Groupe Hospitalier Diaconesses - Croix Saint-Simon — Paris, France (Recruiting)
- Hôpital Cochin — Paris, France (Recruiting)
- Hôpital Européen Georges Pompidou — Paris, France (Recruiting)
- Institut Curie — Paris, France (Recruiting)
- Clinique Francheville — Périgueux, France (Recruiting)
- HCL - Centre Hospitalier Lyon Sud — Pierre-Bénite, France (Recruiting)
- CHU de Poitiers - Hôpital de la Milétrie — Poitiers, France (Recruiting)
- Centre Eugène Marquis — Rennes, France (Recruiting)
- ICO - Centre René Gauducheau — Saint-Herblain, France (Recruiting)
- Oncopole Claudius Regaud - IUCT Oncopole — Toulouse, France (Recruiting)
- Clinique Pasteur — Toulouse, France (Recruiting)
- ICL - Centre Alexis Vautrin — Vandœuvre-lès-Nancy, France (Recruiting)
- Gustave Roussy — Villejuif, France (Recruiting)
- Centre Hospitalier Princesse Grace — Monaco, Monaco (Recruiting)
Study contacts
- Study coordinator: Sandra MABALUKIDI
- Email: smabalukidi@arcagy.org
- Phone: 0033 01 84 85 20 23
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.